04/21/2026
Big news from the AHVI family. 💙
Alaska Heart & Vascular Institute, together with the American Heart Association, is advancing hypertrophic cardiomyopathy and ATTR-CM care through earlier diagnosis, stronger care pathways, and practical tools that help clinicians improve coordination across specialists and care teams.
AHVI has also been selected as one of just 10 health care centers in the nation to participate in the American Heart Association's Amyloidosis Transthyretin Cardiomyopathy (ATTR-CM) Discovery Initiative, joining institutions like Stanford Medicine, Duke University Health System, and Columbia University Irving Medical Center in a three-year national effort to improve how cardiac amyloidosis is detected and treated across the country. ATTR-CM is a condition in which abnormal protein buildup prevents the heart from functioning properly. It's life-threatening, frequently underdiagnosed, and often caught late, when treatment is less effective. Earlier detection and coordinated, specialist-led care make a real difference for patients and families.
For Alaskans, this means you no longer have to leave the state to access nationally recognized specialty care for these conditions. This recognition belongs to every member of the AHVI clinical and support team. Thank you for all you do for our patients and our community.
More details on our HCM program are coming soon. In the meantime, learn more about the ATTR-CM Discovery Initiative: heart.org/ATTRCMDiscovery